MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum

MetaVia (Nasdaq: MTVA) announced that CEO Hyung Heon Kim will speak at the Life Sciences Virtual Investor Forum on March 12, 2026 at 10:30 am ET, discussing the company's pipeline of novel obesity and metabolic therapies.

Rhea-AI Summary

MetaVia (Nasdaq: MTVA) announced that CEO Hyung Heon Kim will speak at the Life Sciences Virtual Investor Forum on March 12, 2026 at 10:30 am ET, discussing the company's pipeline of novel obesity and metabolic therapies.

The session is a live, interactive webcast with archived access available; one-on-one investor meetings and pre-registration are offered.

Argus Mar 4 session

+3.21% close to close 0.4x rel. volume Open Argus

Details

News Market Reaction – MTVA

On Mar 4, the day this news came out, MTVA closed 3.21% above the previous close.

Data tracked by StockTitan Argus for the Mar 4 session.

Key Figures

Investor forum date: March 12, 2026 Presentation time: 10:30 am ET

Investor forum date

March 12, 2026

Life Sciences Virtual Investor Forum presentation date

Presentation time

10:30 am ET

Scheduled start time for MetaVia fireside chat

Historical Context

5 past events · Latest: Feb 17

5 events

1. Feb 17

   Conference appearance

   24h Move

   -6.1%

   Announcement of Emerging Growth Conference presentation and Q&A access for investors.

2. Feb 13

   IP and pipeline

   24h Move

   -1.2%

   Global patent portfolio for DA-1726 and supportive obesity efficacy and safety data.

3. Feb 04

   AI collaboration data

   24h Move

   -2.1%

   Positive AI-modeling results validating targets for vanoglipel in MASH and diabetes.

4. Jan 16

   Equity offering

   24h Move

   -3.5%

   $9.3M underwritten public offering with Series C and D warrants for DA-1726 funding.

5. Jan 05

   Clinical trial results

   24h Move

   -8.7%

   Phase 1b DA-1726 data showing strong weight loss and metabolic improvements over 8 weeks.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

cardiometabolic

1 terms

cardiometabolic medical

"a clinical-stage biotechnology company focused on transforming cardiometabolic diseases"

Cardiometabolic describes health conditions that affect the heart and the body’s metabolism—most commonly heart disease, high blood pressure, type 2 diabetes and obesity—that often occur together and share common causes. Investors care because these linked conditions drive large, predictable demand for drugs, medical devices and long-term care, and changes in treatment options, guidelines or costs can materially affect healthcare company revenues and government spending much like a problem in an engine and its fuel system impacts the whole vehicle.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., March 4, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer, will participate in a fireside chat highlighting the company's pipeline of novel obesity and metabolic therapies at the Life Sciences Virtual Investor Forum, co-hosted by Zacks Small Cap Research, on Thursday, March 12, 2026 at 10:30 am ET.

This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the live event on the day of the conference, an archived webcast will also be made available after the event.

It is recommended that investors pre-register using this link and run the online system check to expedite participation and receive event updates.

MetaVia will be available for one-on-one meetings, investors may register using this link. To schedule a meeting with management outside of the conference, please contact Michael Miller at mmiller@rxir.com.

About MetaVia
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing vanoglipel (DA-1241) for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. In a Phase 1 multiple ascending dose (MAD) trial in obesity, DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist reduction. Vanoglipel is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, vanoglipel demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control. In a Phase 2a clinical study, vanoglipel demonstrated direct hepatic action in addition to its glucose lowering effects.

For more information, please visit www.metaviatx.com.

Contacts:

MetaVia
Marshall H. Woodworth
Chief Financial Officer
+1-857-299-1033
marshall.woodworth@metaviatx.com

Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/metavia-to-highlight-novel-obesity-and-metabolic-therapies-at-upcoming-life-sciences-virtual-investor-forum-302703568.html

SOURCE MetaVia Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will MetaVia (MTVA) present at the Life Sciences Virtual Investor Forum?

MetaVia will present on March 12, 2026 at 10:30 am ET. According to the company, the CEO will participate in a live fireside chat and the event will include real-time investor Q&A and an archived webcast afterward.

Who will represent MetaVia (MTVA) at the March 12, 2026 investor forum?

Hyung Heon Kim, President and CEO, will represent MetaVia. According to the company, he will participate in a fireside chat focused on the company's obesity and metabolic therapy pipeline and answer investor questions live.

How can investors access the MetaVia (MTVA) webcast if they cannot join live on March 12, 2026?

An archived webcast will be made available after the live event. According to the company, attendees who miss the live session can view the recorded presentation and follow-up materials posted after the conference.

Can investors schedule one-on-one meetings with MetaVia (MTVA) around the March 12, 2026 forum?

Yes, MetaVia will be available for one-on-one meetings during the conference. According to the company, investors may register for meetings via the provided link or contact Michael Miller to schedule meetings outside the event.

What topics will MetaVia (MTVA) cover in its March 12, 2026 fireside chat?

The fireside chat will highlight MetaVia's pipeline of novel obesity and metabolic therapies. According to the company, the discussion will focus on therapeutic programs, clinical-stage progress, and the company's cardiometabolic strategy.

How should investors prepare to participate in MetaVia's (MTVA) live March 12, 2026 session?

Investors are advised to pre-register and run the online system check to expedite participation. According to the company, preregistration ensures event updates, real-time Q&A access, and faster entry to the live webcast.